Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Pennsylvania for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Pennsylvania only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Pennsylvania (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sameer Gupta (NPI 1013171420)

Field	Value
Entity Type	Individual
Organization	Sameer Gupta
Address	825 Old Lancaster Rd
City	Bryn Mawr
State	PA
ZIP	19010
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 15, 2008

Payer Source	Total Paid
Medicare	$2.9M
Medicaid	$0

Key Findings

This provider’s billing is concentrated in Medicare with Total Medicare revenue: $2.9M and no Medicaid billing on file, making the practice effectively single-payer from a public-program perspective and highly dependent on Medicare volume for scale and revenue continuity. The absence of Medicaid activity means payor diversification is limited and any payer strategy or contracting should focus on Medicare advantage and commercial complements.

Revenue is highly concentrated in a few drug administrations: the precomputed top 3 codes account for 65.1% of this provider's total Medicare revenue, driven by J9271, Q5122, and J0881. Specifically, J9271 contributes $1.3M (45.9%), Q5122 contributes $341.5K (12.2%), and J0881 contributes $191.8K (6.9%), indicating a small number of high-value therapeutics dominate the financial profile.

The code mix identifies an infusion-centered oncology practice: high-volume use of J9271 (pembrolizumab), Q5122 (pegfilgrastim-apgf biosimilar) and frequent chemotherapy administration codes such as 96413 and add-on infusion codes like 96417. This combination of immunotherapy, supportive biologics, and chemotherapy administration suggests the operation functions primarily as an outpatient infusion and oncology treatment site rather than a primarily consultative clinic.

Q5122 stands out as a national outlier: Q5122 has 3.9K claims, $341.5K revenue and ranks #1 of 239 providers nationally (100th percentile; extreme outlier, far above typical national volume), indicating this provider is a dominant national biller for this pegfilgrastim biosimilar and likely a major dispenser or administrator of that product. That rank and claim volume position the practice as uniquely concentrated in pegfilgrastim-apgf relative to peers.

J9271 and J0881 show strong national standing for key oncology biologics: J9271 has 29.8K claims, $1.3M revenue and ranks #121 of 1841 (93th percentile; notably above typical national volume), while J0881 has 95.9K claims, $191.8K revenue and ranks #6 of 1114 (99th percentile; extreme outlier, far above typical national volume). Together these rankings indicate above-typical to extreme usage of both immunotherapy and erythropoiesis-stimulating agent administrations versus national peers.

Procedure and visit volumes reinforce high treatment throughput: 96413 (1.2K claims, $126K revenue) ranks #39 of 7514 (99th percentile; extreme outlier) and 96375 (4.7K claims, $60.8K revenue) ranks #5 of 5191 (100th percentile; extreme outlier), while office E/M 99214 (1.8K claims, $175K revenue) ranks #2178 of 479517 (100th percentile; extreme outlier). These elevated percentiles across infusion and E/M codes are consistent with a high-volume infusion practice that also carries substantial follow-up and management visits.

The provider also bills for ancillary infusion- and program-related items: M0010 (461 claims, $32.3K revenue) ranks #5 of 544 (99th percentile; notably above typical national volume), and multiple infusion add-on codes (96417, 96401, 96367) appear in the top codes list. High relative ranking on M0010 signals active participation in enhanced oncology model monthly payments, suggesting alignment with oncology care management and quality/payment innovation programs.

The NPI was enumerated on 2008-07-15 (~18 years ago), indicating a long-tenured practice that likely benefits from an established referral network and operational stability. Given the tenure and the concentrated, high-volume infusion profile, strategic considerations should focus on managing Medicare dependence, securing supply/administration arrangements for dominant biologics, and evaluating opportunities to diversify payor mix or expand commercial contracts.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

46 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	29,800	$40	$1.3M
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	3,880	$90	$341.5K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	95,900	$1	$191.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,750	$100	$175K
J0897	Injection, denosumab, 1 mg	9,480	$20	$170.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,170	$110	$126K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	3,300	$30	$112.2K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	460	$150	$66.4K
96375	Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the…	4,680	$10	$60.8K
J1439	Injection, ferric carboxymaltose, 1 mg	51,750	$1	$51.8K

Showing 1–10 of 46

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 46 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Pennsylvania Distribution

Sameer Gupta — 14 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Pennsylvania

Full comparison — all codes billed, vs. state median

46 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	40	13,000	$40	$604.4K
J0897	72	530	2,460	$20	$89.6K
J1568	2	10	1,930	$30	$73K
J0881	2	50	24,690	$1	$72.7K
Q5122	1	30	440	$90	$57.4K
J1437	26	60	3,050	$20	$52.3K
J1439	14	60	27,000	$1	$36K
J3490	2	110	60	$70	$27.9K
96413	2	300	140	$100	$19.8K
M0010	1	10	210	$70	$16K

Showing 1–10 of 46

Related Providers

Other providers that share a Tax Identification Number (TIN) with Sameer Gupta, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Agnesian Healthcare, Inc	WI	General Acute Care Hospital	$0	$17.8M
Agnesian Healthcare, Inc	WI	Community Based Hospice Care Agency	$0	$8.8M
Agnesian Healthcare Inc	WI	Family Medicine Physician	$0	$7.4M
Agnesian Healthcare Inc	WI	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$2.3M
Donald Miller	PA	Rheumatology Physician	$2.2M	$0
John Devlin	PA	Hematology & Oncology Physician	$2M	$0
Bmmsa Heart & Vascular Center Of The Main Line	PA	Ambulatory Surgical Clinic/Center	$1.9M	$0
Nancy Walker	PA	Rheumatology Physician	$1.7M	$0
Stephanie Flagg	PA	Rheumatology Physician	$1.6M	$0
Sean Curran	PA	Cardiovascular Disease Physician	$1.4M	$0

Nearby Providers

Other providers in the same ZIP code as Sameer Gupta, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Kaleidoscope Family Solutions, Inc.	PA	Community/Behavioral Health Agency	$0	$78.3M
Resources For Human Development, Inc.	PA	Community/Behavioral Health Agency	$0	$30.7M
Kaleidoscope Family Solutions Aba Inc.	PA	Behavior Analyst	$0	$9.8M
Academic Urology Of PA, LLC	PA	Ambulatory Surgical Clinic/Center	$1.5M	$0
Bryn Mawr Surgery Center LLC	PA	Ambulatory Surgical Clinic/Center	$1.3M	$0
Kara Capriotti	PA	Dermatology Physician	$1.1M	$0
Tarun Mathur	PA	Cardiovascular Disease Physician	$1.1M	$0
Bryn Mawr Medical Specialists Association	PA	Ambulatory Surgical Clinic/Center	$886K	$0
John Fisher	PA	Cardiovascular Disease Physician	$810.9K	$0
John Steers	PA	Cardiovascular Disease Physician	$767.7K	$0

Sameer Gupta — Billing Profile & Reimbursement Data

Sign up for Sameer Gupta — Billing Profile & Reimbursement Data policy alerts

Sameer Gupta — Billing Profile & Reimbursement Data

Sign up for Sameer Gupta — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References